

Associate Professor Peter Wong

Head, Dept of Rheumatology, Westmead Hospital,
Chair, Healthy Bones Australia
Medical & Scientific Advisory Committee, *SYDNEY*

Associate Professor Peter Wong is Head of the Rheumatology Department at Westmead Hospital, Sydney, and Chair of the Healthy Bones Australia (formerly, Osteoporosis Australia) Medical and Scientific Advisory Committee – appointed in February 2021.

He also serves as a Clinical Associate Professor in the Sydney Medical School; MD Research Coordinator at the Westmead Clinical School; and Conjoint Associate Professor in the UNSW Rural Clinical School.

Prior to assuming his role at Westmead Hospital in February 2019, A/Prof Wong spent 11 years in clinical practice in the regional city of Coffs Harbour, NSW, where he helped establish the first Fracture Prevention Clinic and the first Pulmonary Arterial Hypertension Service in regional Australia. Nowadays, he continues to visit Coffs Harbour regularly, offering his specialist services to those in need.

A/Prof Wong is passionate about improving osteoporosis care in Australia and raising awareness about bone health. He strongly advocates for improved management of osteoporosis and encourages health professionals to utilise the advances in diagnosis and treatment to capture patients at-risk.

A/Prof Wong completed his PhD focusing on the molecular biology of inflammatory arthritis and bone disease at the WEHI/Melbourne University in 2006. He then completed a Graduate Diploma in Clinical Epidemiology and Biostatistics at Newcastle University, graduating in 2007.

A/Prof Wong specialises in the biologic treatment of inflammatory arthritis, osteoporosis, pulmonary arterial hypertension, vaccination in rheumatology patients and point-of-care ultrasound. His current research interests include the use of musculoskeletal (MSK) US in improving medication adherence; assessment of osteoporosis refracture prevention models of care; bone health in men commencing androgen deprivation therapy for prostate cancer; and vaccination in patients commencing biological and targeted synthetic disease-modifying, anti-rheumatic drugs (b/tsDMARDs) in the management of rheumatoid arthritis.

ends#



MEDIA CONTACTS:

Kirsten Bruce & Millie Chamberlain
VIVA! Communications

M 0401 717 566 | 0404 568 615

T 02 9968 3741 | 02 9968 3741

E kirstenbruce@vivacommunications.com.au /

millie@vivacommunications.com.au